In December 2025, a headline most men never expected to see broke through the noise: an FDA expert panel recommended that testosterone should no longer be treated like a dangerous drug.
On December 10, 2025, the FDA convened a panel of urologists, endocrinologists, and men's health researchers to re-evaluate how testosterone replacement therapy (TRT) is regulated in the United States. The panel's conclusion was unanimous and sweeping: the rules that have governed testosterone since 1990 are outdated, not supported by modern evidence, and are actually contributing to undertreatment and unsafe gray-market workarounds.
For millions of American men experiencing symptoms of low testosterone, the moment felt significant. Testosterone has spent decades at a strange intersection of medicine, stigma, sports doping headlines, and internet hype.
So what actually changed? What didn't? And if you're a man considering getting tested in 2026, what do you need to know before starting a conversation with a doctor? If you want answers to these questions, keep reading.
What the FDA Panel Recommended in December 2025?
The December 2025 meeting was not a standard FDA approval meeting. It was an expert panel called to discuss whether current testosterone labeling and regulation still make sense.
The panel made three core recommendations:
- Remove testosterone from the Schedule III controlled substance classification. Testosterone is a DEA Schedule III substance, which includes the other substances found in this section, such as ketamine and codeine. At the time, the DEA and the American Medical Association disagreed, saying that there was no evidence of physical dependence at therapeutic doses. The panel raised concerns that the classification imposes a prescription barrier, pharmacy burden, and stigma that deters proper care.
- Expand FDA-approved indications to include age-related low testosterone. At this time, TRT is only FDA-approved for men with a known structural or genetic cause for low testosterone (classical hypogonadism), such as Klinefelter, a pituitary tumor, or injury to the testicles. They have a limitation of use: Safety and effectiveness for use in age-related hypogonadism have not been proven. The panel recommended that the FDA follow recommendations by the American Urological Association (AUA) and the Endocrine Society to treat men with symptoms and known low levels, regardless of what causes them.
- Remove prostate cancer contraindications from labeling . The panel pointed to recent research that contradicted the "Huggins hypothesis," which was decades old and cited as the basis for the warning, and which has not been substantiated by modern evidence as a reason for not recommending TRT.
Crucially, this was a recommendation, not a regulatory change.
As of August 2026, testosterone remains Schedule III, and the indication has not been formally expanded. In April 2026, the FDA took a measured next step, publishing a Federal Register notice encouraging manufacturers to submit supplemental applications for a new indication: low libido associated with idiopathic hypogonadism. The FDA also issued a Request for Information (Docket FDA-2025-N-6743) that received over 2,000 public comments. No final rule has been issued yet.
In short, the cultural shift is real, but the legal framework hasn't changed yet.
What the Research Actually Says About TRT Safety in 2026?
Much of the panel's confidence came from one study: TRAVERSE.
TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) was the largest randomized, placebo-controlled cardiovascular safety trial of testosterone ever conducted. It enrolled 5,246 men aged 45 to 80 who had documented low testosterone and either pre-existing cardiovascular disease or multiple cardiovascular risk factors.
The results, published in 2023, were straightforward: TRT was non-inferior to placebo for major adverse cardiovascular events (MACE), defined as nonfatal heart attack, nonfatal stroke, or death from cardiovascular causes. MACE occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group.
That finding directly led the FDA to remove the boxed warning about increased risk of heart attack and stroke from all testosterone products in February 2025 6.
But TRAVERSE also provided nuance that responsible coverage should include. The trial found a higher incidence in the testosterone group of:
- Pulmonary embolism (0.9% vs. 0.5%)
- Atrial fibrillation (3.5% vs. 2.4%) and nonfatal arrhythmias requiring intervention (5.2% vs. 3.3%)
- Acute kidney injury (2.3% vs. 1.5%)
These signals mean clinicians are advised to use caution and counseling in men with a history of venous thromboembolism, arrhythmia, or kidney injury.
What about prostate cancer? The TRAVERSE data showed no significant difference in prostate cancer incidence between TRT and placebo, aligning with multiple large observational studies. The Endocrine Society and AUA now state there is no evidence that TRT increases prostate cancer risk, though monitoring is still required.
Current guidelines agree on monitoring essentials: hematocrit (to watch for polycythemia, which means thickening of blood), PSA for prostate health, and estradiol and testosterone levels to ensure dosing is physiologic. The real, evidence-based risks that require management are not the headlines from a decade ago, but practical issues: polycythemia, testicular atrophy and reduced sperm production (leading to infertility while on therapy), acne, and mild fluid retention.
Who Should Actually Consider Testosterone Therapy?
TRT is not suitable for all men who are feeling tired. The threshold is clearly defined in professional guidelines.
Evaluation should be considered in men with persistent symptoms and biochemically low testosterone (total testosterone < 300 ng/dL on two separate morning tests (before 10 am) using a reliable assay) of the level of testosterone, according to the AUA and Endocrine Society.
Symptoms that help with diagnosis are:
- Low libido and/or changes in erectile function that do not improve with time
- Tiredness and diminished sense of well-being with good sleep
- A reduction in muscle mass or strength and an increase in the amount of body fat, even when diet/exercise is unchanged
- Lack of interest or enjoyment, irritability, or difficulty concentrating
- A decrease in the amount of calcium in bones.Low bone mineral density.
Lifestyle comes first. Other factors that are known to lower levels of T include poor sleep, chronic stress, excessive drinking, obesity, and an untreated sleep apnea disorder. Guidelines suggest that these be taken care of before or in conjunction with TRT. In many men, just losing weight can increase their T by 50-100 ng/dl.
But who really is under-treated? The data that was presented before the committee showed middle-aged men (ages 40-64), men in rural areas who don't have access to urology or endocrinology, and men who are uninsured or underinsured, who either don't go to specialty care or are deterred by the cost and stigma of the service. About 5.6% of men between the ages of 30 and 79 have low testosterone levels that are clinically significant, and only a small number have been assessed. The panel said that the overly conservative labeling has driven men away from guidelines-based care and into alternative care that is not regulated.
TRT is not recommended for men who have normal levels of testosterone and want to improve their performance or build muscle, since the purpose of the treatment is to restore it, and for anti-aging. This application is not indicated, not supported by guidelines, and has other risk-benefit considerations.
How Men Are Actually Accessing TRT Now?
The old system was simple: patients would go to Primary Care, then be referred to Urology or Endocrinology, go to labs, and pick up their medication at the pharmacy. This track is still a good option and may be best for men who have complicated health needs.
However, it's also slow. The average person has to wait over 30 days to get a new doctor's appointment in urology in the U.S., and many men say that they do not want to share sexual and energy symptoms with a doctor.
That divide has been a driving force behind the growth of telehealth. Legitimate telemedicine platforms have developed models that are similar to an in-person setup, which includes at-home or Labcorp/Quest lab testing for total and free testosterone, LH, FSH, hematocrit, PSA, and estradiol; video sessions with a licensed physician in your state; and regular monitoring every 3-6 months with adjustments to the dosage and safety testing.
The key distinction for patients is between medically supervised care and illegal sellers. Legitimate online clinics require: verified labs, medical history review, licensed physician oversight, prescriptions filled through U.S. pharmacies, and continuous follow-up. They will not prescribe if labs are normal, if contraindications exist, or without monitoring. Illegal or overseas sellers offering testosterone without a prescription, without labs, or without physician review are not TRT. They are unregulated drug distribution and carry significant health and legal risks.
For men researching options, understanding what good telehealth looks like helps set expectations. Reputable models like medically supervised TRT programs like this online TRT clinic show how the process is supposed to work: labs first, physician evaluation, then treatment only if clinically indicated, with ongoing lab tracking.
This shift toward telehealth was explicitly discussed by the FDA panel. Panelists noted that Schedule III status creates prescribing hurdles that discourage primary care doctors from offering TRT, pushing patients toward cash-based "low T clinics" that may not follow guidelines. Removing barriers, they argued, could bring care back into guideline-based practices, whether in person or via telehealth.
What to Expect from Treatment (If You Qualify)
If you are determined to be eligible for TRT by a licensed provider, TRT is not a quick fix. It's a restoration project that will take months.
Most men experience a notable decrease in energy, mood, and libido within 3–6 weeks, at which point the levels are in a steady physiologic state. The changes in body composition: increased lean mass, decreased fat mass, and strength improvements will take 3–6 months and are highly dependent on resistance training, protein intake, and sleep. It takes 12 months or more to see bone density improvements.
The following forms are available for 2026:
- Testosterone cypionate/enanthate (injectable): Most frequently and cheaply used, usually injected every week or every other week. Stable in the presence of adequate doses
- Topical gels: Applied daily, can lead to steady levels, may be transferred to partners/children if not applied properly.
- Patches and nasal gels: These are less common but are available for those who do not want to use an injection.
- Oral alternatives that preserve fertility: For younger men who want to maintain their fertility, oral alternatives may be discussed, such as medications that cause the body to produce more natural testosterone. This is distinct from exogenous (outside of the body) testosterone.
Monitoring cadence is consistent across guidelines: labs at baseline, 3 months after initiation or dose change, then every 6-12 months if stable. Providers track total and free testosterone, hematocrit, PSA (in men over 40), estradiol, and blood pressure. If hematocrit rises above ~54%, dose adjustment, therapeutic phlebotomy, or discontinuation is considered.
What TRT Cannot Do (And Why That Matters)
An honest section is essential for credibility, especially on MedicalDaily.
TRT is not a fountain of youth. It will not fix depression alone if the underlying cause is untreated major depressive disorder, trauma, or burnout. It will not fix poor sleep alone if you have untreated severe sleep apnea or chronic 5-hour nights. It will not fix low libido alone if the core issues are relationship conflict, chronic stress, or medication side effects.
It also will not transform body composition without training and nutrition. Testosterone restores the hormonal environment that makes building muscle and losing fat more physiologically possible; it does not replace the stimulus.
And it is not appropriate for men with normal testosterone levels seeking a performance edge. In men with normal levels, adding exogenous testosterone suppresses natural production, shrinks testicular volume, impairs fertility, and increases risk of polycythemia and cardiovascular strain without guideline-supported benefit.
Understanding these limits is what separates medical therapy from marketing. The most responsible providers will tell some men not to start.
A Shift, Not a Free-for-All
The December 2025 FDA panel did not declare testosterone risk-free. It declared that the regulations built on 1990s fears no longer match 2026 evidence.
TRAVERSE gave us reassurance on major cardiovascular events, but also reminders about clots and arrhythmias. Guidelines give us clear thresholds for who should be tested. Telehealth has made testing and follow-up more accessible, but only when it follows the same medical standards as in-person care.
If you have symptoms that align with low testosterone, the bottom line has not changed: get tested with two morning labs, review lifestyle factors, and work with a licensed provider who requires labs, monitors safety markers, and is willing to say no if you don't qualify. The FDA's cultural signal may eventually make that process easier, but good medicine still requires careful evaluation.
